Priscilla K Brastianos

Summary

Affiliation: Massachusetts General Hospital
Country: USA

Publications

  1. doi request reprint Primary central nervous system lymphoma: overview of current treatment strategies
    Priscilla K Brastianos
    Stephen E and Catherine Pappas Center for Neuro Oncology, Division of Hematology and Oncology, Department of Neurology, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA 02114, USA
    Hematol Oncol Clin North Am 26:897-916. 2012
  2. doi request reprint Vascular endothelial growth factor inhibitors in malignant gliomas
    Priscilla K Brastianos
    Stephen E and Catherine Pappas Center for Neuro Oncology, Department of Neurology, Division of Hematology and Oncology, Massachusetts General Hospital Cancer Center, Boston, MA, USA
    Target Oncol 5:167-74. 2010
  3. doi request reprint The toxicity of intrathecal bevacizumab in a rabbit model of leptomeningeal carcinomatosis
    Priscilla K Brastianos
    Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, 44 Binney Street, Smith 353, Boston, MA 02115, USA
    J Neurooncol 106:81-8. 2012
  4. pmc Genomic analysis of diffuse pediatric low-grade gliomas identifies recurrent oncogenic truncating rearrangements in the transcription factor MYBL1
    Lori A Ramkissoon
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Proc Natl Acad Sci U S A 110:8188-93. 2013
  5. ncbi request reprint VEGF inhibitors in brain tumors
    Priscilla K Brastianos
    Department of Medical Oncology, Dana Farber Brigham and Women s Cancer Center, Massachusetts General Hospital, Boston, 02114, USA
    Clin Adv Hematol Oncol 7:753-60, 768. 2009
  6. pmc Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas
    Priscilla K Brastianos
    1 Division of Hematology Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA 2 Division of Neuro Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA 3 Harvard Medical School, Boston, Massachusetts, USA 4 Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA 5 Broad Institute of MIT and Harvard, Boston, Massachusetts, USA 6
    Nat Genet 46:161-5. 2014
  7. pmc Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations
    Priscilla K Brastianos
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA
    Nat Genet 45:285-9. 2013

Collaborators

Detail Information

Publications7

  1. doi request reprint Primary central nervous system lymphoma: overview of current treatment strategies
    Priscilla K Brastianos
    Stephen E and Catherine Pappas Center for Neuro Oncology, Division of Hematology and Oncology, Department of Neurology, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA 02114, USA
    Hematol Oncol Clin North Am 26:897-916. 2012
    ..The standard treatment is a methotrexate-containing chemotherapy regimen. The timing and dose of whole-brain radiation therapy is controversial, given the significant risks of late neurotoxic effects, particularly in elderly patients...
  2. doi request reprint Vascular endothelial growth factor inhibitors in malignant gliomas
    Priscilla K Brastianos
    Stephen E and Catherine Pappas Center for Neuro Oncology, Department of Neurology, Division of Hematology and Oncology, Massachusetts General Hospital Cancer Center, Boston, MA, USA
    Target Oncol 5:167-74. 2010
    ..Unfortunately, antiangiogenic treatment inevitably fails in most patients. Further studies are needed to understand the molecular pathways that enable a tumor to evade antiangiogenic therapy...
  3. doi request reprint The toxicity of intrathecal bevacizumab in a rabbit model of leptomeningeal carcinomatosis
    Priscilla K Brastianos
    Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, 44 Binney Street, Smith 353, Boston, MA 02115, USA
    J Neurooncol 106:81-8. 2012
    ..This neurotoxicity study provides safety data to allow phase I/II studies in humans with treatment refractory LC...
  4. pmc Genomic analysis of diffuse pediatric low-grade gliomas identifies recurrent oncogenic truncating rearrangements in the transcription factor MYBL1
    Lori A Ramkissoon
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Proc Natl Acad Sci U S A 110:8188-93. 2013
    ..Our results define clinically relevant molecular subclasses of diffuse PLGGs and highlight a potential role for the MYB family in the biology of low-grade gliomas...
  5. ncbi request reprint VEGF inhibitors in brain tumors
    Priscilla K Brastianos
    Department of Medical Oncology, Dana Farber Brigham and Women s Cancer Center, Massachusetts General Hospital, Boston, 02114, USA
    Clin Adv Hematol Oncol 7:753-60, 768. 2009
    ..Unfortunately, treatment inevitably fails. Further studies are needed to understand mechanisms of tumor resistance and to identify other therapeutic targets that mediate angiogenesis...
  6. pmc Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas
    Priscilla K Brastianos
    1 Division of Hematology Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA 2 Division of Neuro Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA 3 Harvard Medical School, Boston, Massachusetts, USA 4 Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA 5 Broad Institute of MIT and Harvard, Boston, Massachusetts, USA 6
    Nat Genet 46:161-5. 2014
    ..Adamantinomatous and papillary craniopharyngiomas harbor mutations that are mutually exclusive and clonal. These findings have important implications for the diagnosis and treatment of these neoplasms. ..
  7. pmc Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations
    Priscilla K Brastianos
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA
    Nat Genet 45:285-9. 2013
    ..These mutations were present in therapeutically challenging tumors of the skull base and higher grade. These results begin to define the spectrum of genetic alterations in meningiomas and identify potential therapeutic targets...